Bio-Rad Laboratories (BIO) Gets a Hold from Wells Fargo
In a report released today, Brandon Couillard from Wells Fargo maintained a Hold rating on Bio-Rad Laboratories, with a price target of $340.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Couillard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Danaher, and Exact Sciences. According to TipRanks, Couillard has an average return of 17.5% and a 62.71% success rate on recommended stocks.
In a report released on December 9, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $315.00 price target.
Based on Bio-Rad Laboratories’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $653 million and a GAAP net loss of $341.9 million. In comparison, last year the company earned a revenue of $649.73 million and had a net profit of $653.17 million
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIO in relation to earlier this year. Last month, JAMES BARRY, the EVP, President, LSG of BIO sold 699.00 shares for a total of $214,019.82.
Read More on BIO:
